MoonLake Immunotherapeutics (MLTX) Total Current Liabilities (2020 - 2026)

MoonLake Immunotherapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $46.1 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 92.29% year-over-year to $46.1 million; the TTM figure through Mar 2026 stood at $46.1 million (up 92.29% YoY), while the FY2025 annual figure was $45.5 million, up 102.46% from the prior year.
• Total Current Liabilities was $46.1 million for Q1 2026 at MoonLake Immunotherapeutics, up from $45.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $202.8 million in Q1 2022 to a low of $3.9 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $30.0 million across 5 years, with a median of $12.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 337883.77% in 2022, then tumbled 96.41% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $7.7 million in 2022, then jumped by 30.01% to $10.0 million in 2023, then soared by 125.4% to $22.5 million in 2024, then jumped by 102.46% to $45.5 million in 2025, then gained by 1.4% to $46.1 million in 2026.
• The last three Total Current Liabilities figures came in at $46.1 million (Q1 2026), $45.5 million (Q4 2025), and $48.4 million (Q3 2025), per Business Quant data.